Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117). It has been shown to significantly inhibit growth of breast cancer in xenograft models and has been successful in trials with renal cell carcinoma (RCC) and several other tumor types.
A Phase II clinical trial ...
More
Read article at Wikipedia
Axitinib
Facts from the Community
From the BioVenturist base
Developed by:
Stage of development:
We can tell you that Axitinib is a
If you know more about Axitinib, you can add more facts here »
Similar topics in Freebase
You can help improve this topic by adding more facts here